Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma.
Wasko UN, Jiang J, Curiel-Garcia A, Wang Y, Lee B, Orlen M, Drizyte-Miller K, Menard M, Dilly J, Sastra SA, Palermo CF, Dalton T, Hasselluhn MC, Decker-Farrell AR, Chang S, Jiang L, Wei X, Yang YC, Helland C, Courtney H, Gindin Y, Zhao R, Kemp SB, Clendenin C, Sor R, Vostrejs W, Amparo AA, Hibshman PS, Rees MG, Ronan MM, Roth JA, Bakir B, Badgley MA, Chabot JA, Kluger MD, Manji GA, Quintana E, Wang Z, Smith JAM, Holderfield M, Wildes D, Aguirre AJ, Der CJ, Vonderheide RH, Stanger BZ, Singh M, Olive KP.
Wasko UN, et al. Among authors: palermo cf.
bioRxiv [Preprint]. 2023 Dec 4:2023.12.03.569791. doi: 10.1101/2023.12.03.569791.
bioRxiv. 2023.
PMID: 38105998
Free PMC article.
Preprint.